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Introduction 
Synaptic transmission is a rapid form of communication that involves the rapid (µs) diffusion of a 
high concentration (mM) of transmitters over a short distance (nm) between pre- and postsynaptic 
sites. An alternative form of chemical communication, non-synaptic transmission, also exists within 
the central nervous system (CNS) (Vizi 1984; Vizi 2000), providing a much slower (ms – s) means 
of communication that operates over longer diffusion distances (µm), uses relatively low transmitter 
concentrations (nM-µM) and exerts tonic influences. Synaptic functions are thought to be 
responsible for tasks that require high speed and precision, such as visual pattern recognition and 
motor pattern execution. Conversely, non-synaptic functions are thought to be responsible for 
modulating and tuning these processes by providing the emotional, attentional and motivational 
context. Many neurological and psychiatric disorders involve disturbances of these fine modulations 
and, therefore, have been most effectively combated by targeting the nonsynaptic modulatory 
system. Indeed, almost all pharmacological manipulations of the CNS are restricted to this latter 
realm, which predominantly involves nonsynaptic functions (Vizi, Fekete et al. 2010). Competitive 
antagonists preferentially affect nonsynaptic receptors because it is easier for the antagonist to 
displace agonists at low extrasynaptic concentrations than at high synaptic concentrations. 
Similarly, agents that inhibit transport systems predominantly affect the nonsynaptic systems 
because a minor increase in ambient concentrations has a large effect on high affinity extrasynaptic 
receptors, while the effect is negligible within the synaptic cleft where low affinity receptors are 
activated by millimolar transmitter concentrations. Thus, it is important to study the functions of 
these receptors and transporters, their sub-cellular distributions, and any functional differences 
(Vizi, Fekete et al. 2010) that depend on physiological and pathological conditions to develop 
effective drugs, particularly those that target extrasynaptic receptor subtypes. 
The primary goal of the present study was to elucidate the function and pharmacology of 
nonsynaptic nicotinic acetylcholine receptors  (nAChRs) (Chiovini, Turi et al. 2010; McCormack, 
Melis et al. 2010; Vizi, Fekete et al. 2010; Mike, Pesti et al. 2011) and NMDA receptors (Vizi, 
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Fekete et al. 2010; Katona, Kaszas et al. 2011; Lendvai, Halmos et al. 2011; Szasz, Fodor et al. 
2011). The involvement of voltage-gated channels in neuropathological processes and possible 
pharmacological approaches for neuroprotection were also investigated. 
 
Nonsynaptic and synaptic NMDA receptors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Glutamate may have neuroprotective or neurodegenerative effects depending on physiological or 
pathophysiological conditions. The role of NR2A and NR2B receptors. Note that NR2A receptors located in 
the synapse, transmit information from the glutamatergic terminals to be neuroprotective. During ischemia 
glutamate released from nerve terminals [Ca2+]o-independently exerts effects on extrasynaptic NR2B 
receptors, producing neurodegeneration. 
 
It has been demonstrated that calcium entry through synaptic NMDA receptors induces cAMP 
response element binding protein (CREB) activity and CREB-evoked brain derived neurotrophic 
factor (BDNF) gene expression (Leveille, El Gaamouch et al. 2008). In contrast, Ca2+ entry through 
non-synaptic NMDA receptors, which is activated by Glu that is added to the bath or released by 
hypoxic/ischaemic conditions, triggers the dominant CREB shut-off pathway and, therefore, blocks 
the induction of BDNF expression (Hardingham, Fukunaga et al. 2002) (Fig. 1). These findings 
indicate that synaptic NMDA receptors exhibit anti-apoptotic activity, whereas the stimulation of 
extrasynaptic NMDA receptors causes a breakdown of the mitochondrial membrane potential(s). 
The latter is an early marker for Glu-induced neuronal damage, ROS generation (Adam-Vizi 2005) 
and cell death. It has also been reported that hypoxic/ischaemic conditions achieved through the 
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stimulation of extrasynaptic Glu receptors may 
activate Ca2+-activated chloride channels (ClCa1) 
(Wahl, Buchthal et al. 2009), which are part of the 
genomic death programme and are also involved in 
causing neuronal damage.  
Thus, NMDA receptor antagonists are expected to 
provide some neuroprotective effects. However, a 
number of clinical trials have failed to demonstrate 
the expected effects of these drugs (Editorial 2006) 
to reduce brain injury or prevent neurodegeneration 
(Ikonomidou and Turski 2002; Kemp and 
McKernan 2002). Recent advances in NMDA 
receptor research have provided an explanation for 
this failure. It has been shown that NR2A subunit-
containing NMDA receptors are mainly located synaptically, whereas NR2B subunits are 
predominantly expressed in extrasynaptic locations and are primarily responsible for NMDA’s 
excitotoxic effects (Leveille, El Gaamouch et al. 2008) (Fig. 2). Compounds that affect both 
subtypes have been studied clinically without any progress. Consequently, in the last few years, the 
specific blockade of non-synaptic NMDA receptors and the development of selective NR2B 
antagonists have begun to dominate the field of neuroprotective drug development. 
Pharmacological studies using NR2B receptor antagonists, therefore, promise interesting and 
clinically relevant results that could lead to the development of drugs for the treatment of dementia, 
acute brain injuries and neurodegenerative diseases.   
 
Mayer A, Szasz BK, Kiss JP. 
Inhibitory effect of antidepressants on the NMDA-evoked [(3)H]noradrenaline release 
from rat hippocampal slices.  
Neurochem Int, 2009, 55, 383-388  
In this study we have shown that desipramine and fluoxetine were able to inhibit the NMDA-
evoked [3H]noradrenaline release with an IC50 14.6 and 41.1 µM, respectively. These two 
antidepressants inhibited only the NMDA-evoked response, they were without effects on the release 
of [3H]noradrenaline evoked by axonal activity. The non-competitive NMDA receptor antagonist 
MK801 also inhibited the release of [3H]noradrenaline produced by NMDA receptor activation. 
These data indicate that the inhibitory effect of antidepressants on NMDA receptors might 
contribute to the therapeutic effect of these drugs. 
 
Figure 2. Nonsynaptic NMDA receptors: 
localisation and possible functions. 
(schematic drawing taken from Vizi et al. (Br. 
J. Pharmac. 160: 785-809, 2010). 
4 
 
Vizi, E. S., Szasz, B. K., Fodor, L., Mike, A., Lenkey, N., Kurko, D., Nagy, J., Kiss, J. P. 
GluN2B-NMDA receptors as possible targets for the neuroprotective and 
antidepressant effects of fluoxetine.  
Neurochem Int, 2012,  accepted for publication 
It is interesting that, although they belong to different superfamilies of ligand-gated ionotropic 
receptors, nAChRs and NMDA receptors share several pharmacological properties. For instance, 
the channel blocker-type nAChR antagonist mecamylamine is able to block NMDA receptors (Snell 
and Johnson 1989), while the channel blocker-type NMDA receptor antagonist MK-801 inhibits 
nAChRs (Ramoa, Alkondon et al. 1990). In addition, fluoxetine and desipramine have been shown 
to inhibit NMDA-evoked inward currents in a dose-dependent manner (Szasz, Mike et al. 2007), 
resulting in similar IC50 values for both drugs (3.13 µM for desipramine and 10.51 µM for 
fluoxetine (Fig. 3)). These concentrations fall in the therapeutically relevant range, suggesting that 
the clinical effects of neuroprotective drugs may involve the inhibition of NMDA receptors (Vizi 
2000; Kiss 2008).  
 
 
 
 
 
 
 
 
 
Fig. 3 Inhibitory effect of fluoxetine (FLX) and desipramine on the NMDA-evoked currents in HEK 293 
cells stably expressing rat recombinant NMDA receptors with NR1a/NR2A or NR1a/NR2B subunit 
compositions. The cells were stimulated with NMDA (10 µM). Each point represents the mean ± S.E.M. of 
4-6 independent experiments. The IC50 values were determined by non-linear regression (Prism 3.0). (Figure 
taken from Vizi et al., Neurochem Int 2012). 
 
 
Lendvai, B., Halmos, G. B., Polony, G., Kapocsi, J., Horvath, T., Aller, M., Vizi, E. S., 
Zelles, T. 
Chemical neuroprotection in the cochlea: the modulation of dopamine release from 
lateral olivocochlear efferents.  
Neurochem Int, 2011, 59, 150-158 
The role of extrasynaptic NR2B subunit-containing receptors in excitotoxicity-related hearing loss 
has also been discussed at length in our review of the neuroprotective role of dopamine in the 
cochlea. We propose that, under conditions of hearing loss resulting from ischaemia, age 
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progression, noise, and aminoglycoside exposure, elevated levels of extracellular glutamate evoke 
excitotoxic effects via nonsynaptic NMDA receptors. 
 
Katona, G., Kaszas, A., Turi, G. F., Hajos, N., Tamas, G., Vizi, E. S., Rozsa, B. 
Roller Coaster Scanning reveals spontaneous triggering of dendritic spikes in CA1 
interneurons.  
Proc Natl Acad Sci USA, 2011, 108, 2148-2153 
Dendrites have long been thought to be electrically passive objects that can be described by the 
cable theory. It has only recently been discovered that dendrites exhibit active conductances and are 
even capable of producing local regenerative activities (dSpikes). It is thought that dSpikes may 
change the mode of integration from linear to supralinear within individual dendritic branches, a 
process that has been proposed to underlie memory formation. To date, such mechanisms have not 
been described for inhibitory interneurons. Using the 3 dimensional scanning method developed in 
our laboratory (which provides uniquely high spatial and temporal resolutions), we detected 
dSpikes in hippocampal interneurons for the first time. Subsequently, we explored the mechanisms 
behind interneuronal dSpikes, investigated the role of NMDA receptors in this phenomenon, and 
described a special integration method (which is unlike that previously reported in excitatory 
pyramidal cells).  
 
Nonsynaptic nAChRs 
 
Investigating this phenomenon in parvalbumin-positive GABAergic interneurons is important 
because clinical studies have shown that working memory impairments are accompanied by  
decreased power and synchrony of gamma oscillations in the brain (Gruber and Muller 2006). This 
effect has been observed in conditions such as psychosis, social withdrawal, and cognitive 
impairment, all of which are symptoms of schizophrenia (Lewis, Hashimoto et al. 2005). Similarly, 
chronic antagonism of NMDA receptors reduces gamma activity in the brain(Cunningham, Hunt et 
al. 2006; Kittelberger, Hur et al. 2011), indicating that NMDA receptors are involved in memory 
impairment, one of the earliest and most consistent manifestations of the disease.  
 
Nicotine, a tertiary amine, has long been recognised as the primary psychoactive agent in tobacco. 
In addition to being an addictive drug, nicotine has many effects in the central nervous system 
(CNS) that are of therapeutic significance (Lloyd, Menzaghi et al. 1998). Nicotine and compounds 
that act on nicotinic receptors exhibit analgesic properties and improve several cognitive functions, 
including attention, learning and memory (Levine, Levine et al. 1998). Nicotine has been shown to 
enhance cognitive functions in both healthy subjects and schizophrenia (SP) patients (Jacobsen, 
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D'Souza et al. 2004; Barr, Culhane et al. 2008). Some studies (Guan, Zhang et al. 1999) have 
reported reduced expressions of α7 nAChRs in the frontal cortices of patients with schizophrenia. 
More importantly, accumulating scientific results support nAChRs as possible therapeutic targets 
for schizophrenia. Given the strong scientific evidence that diminished NMDA receptor activity 
(Gordon 2010) and subsequent cortical GABAergic dysfunction may underlie the pathophysiology 
of psychiatric disorders, including schizophrenia (Benes and Berretta 2001), it is certainly worth 
investigating the effect of nicotine on Ca2+ transients recorded on boutons of parvalbumin-positive 
GABAergic interneurons. Indeed, nicotine has been shown to facilitate the Ca2+ transients in 
boutons in response to soma stimulation(s), indicating that it enhances the release of GABA from 
axon terminals. This effect may help to restore gamma activity, thereby helping to alleviate memory 
dysfunction. In our earlier publication (Sershen, Toth et al. 1995)we firstly provided evidence that 
nicotine acts on preterminal axon able to release transmitter. We have recently shown that nicotine 
facilitates axonal Ca2+ transients measured by 2-foton laser scanning microscopy (unpublished data; 
Fig. 4). 
 
Axon varicosity, 100 µm from soma
CA1 pyramidal neuron, line scan
control
nicotine 1 µM
wash
500 ms
40 %
dF/F
Nicotine facilitates axonal Ca2+ transients by trains
facilitation
 
Fig. 4 The first evidence that nicotine facilitates Ca2+ transient evoked by soma stimulation (unpublished) in 
axonal bouton of Pv+ GABAergic interneurons. Two-photon laser scanning microscopy (for Method see 
Rózsa et al. 2011). The subtype of nAChR remained to be classified. Note the low concentration of nicotine 
acting on varicosities (in the chain-smokers brain nicotine can reach 0.2-2 µM) indicating extrasynaptic 
action. 
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Chiovini, B., Turi, G. F., Katona, G., Kaszas, A., Erdelyi, F., Szabo, G., Monyer, H., 
Csakanyi, A., Vizi, E. S., Rozsa, B. 
Enhanced dendritic action potential backpropagation in parvalbumin-positive basket 
cells during sharp wave activity.  
Neurochem Res, 2010, 35, 2086-2095 
Furthermore, we have studied the modulatory role of nonsynaptic nicotinic receptors on 
backpropagating action potentials in hippocampal parvalbumine positive interneurons. 
Backpropagating action potentials are fundamental to the Hebbian concept of plasticity because 
synaptic potentiation or depression depends on the relative timing of action potentials and synaptic 
inputs. Thus, we investigated the effect of in vitro sharp-wave oscillations on backpropagating 
action potentials. This activity pattern occurs in the hippocampus during the awake resting state, 
consummation (feeding) and slow wave sleep and is, therefore, in contrast to theta oscillation, 
which occurs during exploration. Memory acquisition is hypothesised to take place during the theta 
phase, while memory consolidation is presumed to occur during sharp wave oscillation. We 
observed that, similar to sharp-wave oscillations, activation of nonsynaptic nicotinic receptors 
produced action potential backpropagation-enhancing effects (Fig. 5).  
 
Fig. 5 Effect of nicotine on extrasynaptic nAChRs located on the dendrites of GABA-ergic interneurons. 
Figure from Chiovini et al., 2010. 
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McCormack, T. J., Melis, C., Colon, J., Gay, E. A., Mike, A., Karoly, R., Lamb, P. W., 
Molteni, C., Yakel, J. L. 
Rapid desensitization of the rat α7 nAChR is facilitated by the presence of a proline 
residue in the outer beta-sheet.  
J Physiol (Lond), 2010, 588, 4415-4429 
Alpha7 subunit-containing neuronal nicotinic receptors are the second most abundant nicotinic 
receptors in the CNS (after the alpha4-beta2 subunit-containing type). Their unique properties 
include extremely fast activation and desensitisation, extremely low open probability, and high Ca2+ 
permeability. The receptors are partly synaptic but are more typically extrasynaptic, and both 
activity/location types are distinguishable by their known functions (learning, memory, cognition, 
reward, sensory information processing, motor control, arousal, pain, neuroprotection, etc.). 
Agonists and positive allosteric modulators (PAMs) of α7 nAChRs are prospective pro-cognitive 
drugs for treatment of schizophrenia and different types of dementia, as demonstrated by several 
preclinical and clinical studies. The advantage of PAMs over agonists is that the physiological 
spatio-temporal pattern of neuronal activation is preserved with the former; only α7 nAChR-
mediated signals are augmented. This is the basis of the effectiveness of GABAA receptor PAMs 
(such as benzodiazepines). In the case of α7 nAChRs, however, most PAM compounds have only 
recently been developed, and much less is known about their mode(s) of action. Some very basic 
questions remain unanswered regarding (a) the operation of the α7 nAChR itself, and (b) the effect 
of PAMs on receptor function. 
In this paper we address the operation and the kinetics of the receptor by studying the effect of an 
important mutation on agonist affinity and gating of the receptor.  
 
Mike, A., Pesti, K., Szabo, A., Vizi, E. S. 
Mode of action of the positive modulator PNU 120596 on alpha7 nicotinic receptors.  
Neuropharmacology, submitted for publication 
In recent work (Neuropharmacology, submitted), we investigated the mode of action of PNU 
120596, one of the best known PAMs. For the first time, we determined the maximal open 
probability at the agonist-evoked current peak (3.85 ± 0.72 %), as well as the open probability in the 
presence of the modulator (66.8 ± 6.25 %). We have shown that PNU 120596 is unable to bind to 
the resting state of the receptor; instead, it binds to the desensitised state, thereby re-activating 
desensitised receptors. We observed, however, that a second desensitised state with slower onset 
and recovery kinetics can develop and that this slower desensitised state is insensitive to PNU 
120596. Furthermore, our results indicate that binding of the modulator greatly increases agonist 
affinity by slowing down dissociation. 
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Other nonsynaptic mechanisms 
 
Reactive oxygen species (ROS) production. 
Milusheva E, Baranyi M, Kormos E, Hracskó Z, Sylvester Vizi E, Sperlágh B. 
The effect of antiparkinsonian drugs on oxidative stress induced pathological 
[3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices.  
Neuropharmacology, 2010, 58, 816-825. 
This non-synaptic DA release could serve as a source of further self-amplifying ROS production 
imposing an extra oxidative burden to dopaminergic neurons (Tretter, Sipos et al. 2004) and 
sensitizing them to a relatively mild mitochondrial deficit alternative ROS-producing pathways not 
selective to the dopaminergic neurons, such as direct mitochondrial or microglial superoxide 
production, may also contribute to the oxidative damage of dopaminergic and nondopaminergic 
terminals after rotenone treatment (i.e. on aging patients or on patients suffering from mild PD). 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, which primarily 
affects the aging population. An in vitro model of mitochondrial dysfunction with subsequent 
oxidative stress was elaborated and utilized to study the effect of L-deprenyl and rasagyline, 
currently used for the treatment of Parkinson’s H2O2-induced 3H-dopamine release and formation of 
toxic (Ros and dopamine quinine) compounds in rat striatal slices. For the mechanism see Fig. 1. In 
this paper we suggested that L-deprenyl is a neuroprotective drug! 
 
Role of extracellular adenosine. 
Sperlagh, B., Vizi, E. S. 
The role of extracellular adenosine in chemical neurotransmission in the 
hippocampus and Basal Ganglia: pharmacological and clinical aspects.  
Curr Top Med Chem, 2011, 11, 1034-1046. 
During hypoxia/ischemia not only neurotransmitters such as Glu, GABA, monoamines are released 
due to the reverse operation of transporters, but there is a release of ATP from different cells which 
is immediately decomposed into adenosine and thereby concentration of extracellular adenosine 
increases. The activation of presynaptically located A1 receptors results in a decrease of transmitter 
release (Vizi and Knoll 1971) including Glu  and exerts a neuroprotective action against ischemia 
(Stone, Ceruti et al. 2009).  
Activation of adenosine receptors is another key protection mechanism against excitotoxicity. The 
dynamics of extracellular adenosine, the localisation of receptors, the function of individual 
subtypes and some potential targets for pharmacological intervention have been reviewed in this 
paper.  
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Role of sodium channels in excitotoxicity. 
Activations of NMDA receptors and sodium channels are interconnected in pathological 
overexcitation. The contribution of persistent sodium channels is especially significant (Fig. 1). The 
persistent sodium current amplitude is less than 1% of the transient amplitude (French, Sah et al. 
1990; Hammarstrom and Gage 1998; Stone, Ceruti et al. 2009), but the resulting total current is 
functionally very significant at subthreshold voltages  (Stafstrom, Schwindt et al. 1982; Stafstrom, 
Schwindt et al. 1985; Bean 2007). This persistent current functions by amplifying sub-threshold 
depolarisation and generating an endogenous rhythm (Bean 2007; Tazerart, Vinay et al. 2008). 
Upregulation of the persistent component has been described for most major sodium channel 
isoforms under pathological conditions (e.g., epilepsy, traumatic injury of the nervous system, 
chronic neurodegenerative diseases such as multiple sclerosis or ALS, cardiac ischaemia, long QT 
syndrome, chronic inflammation, various pain syndromes, muscle spasms, etc.). The resulting 
overexcitability is amplified by the increased Ca2+ influx through NMDA receptors.  Overactivation 
of NMDA receptors has been hypothesised to play a pivotal role in producing neuronal death by 
increasing intracellular Ca2+ activated nucleases, cytosolic proteases and kinases, destroying the 
composition of the cell. Due to Na+ entry and the resulting increase in intracellular Na+ 
concentration, the osmotic balance of the cell is also disturbed during persistent depolarisation. The 
entry of Na+ is followed by the passive entry of Cl- ions and water, which causes an increase in the 
cell volume (osmotic swelling) (Fig. 1) and the release of cell contents into the extracellular space. 
These findings indicate that both antagonism of NMDA receptors and inhibition of sodium channels 
are viable strategies against conditions of hyper-excitability (e.g., to prevent neuronal loss after 
stroke and head trauma). 
 
Because of the significant involvement of voltage-gated channels in pathophysiological processes 
of neurodegeneration, we studied the role of sodium channels as well as their pharmacology. 
Sodium channels are not only important targets of anti-epileptic drugs but are also promising 
candidate targets for the treatment of acute and chronic neurodegenerative processes and different 
pain syndromes.  
 
Persistent sodium current is not caused by a specific channel isoform but most probably reflects a 
specific phosphorylation state of the channels. A major challenge in current pharmacological 
research regarding sodium channels is the development of persistent-selective compounds. For this 
reason, it is especially important to understand the different modes of action of different types of 
sodium channel inhibitors. 
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Fekete, A., Franklin, L., Ikemoto, T., Rozsa, B., Lendvai, B., Sylvester Vizi, E., Zelles, T. 
Mechanism of the persistent sodium current activator veratridine-evoked Ca 
elevation: implication for epilepsy.  
J Neurochem, 2009, 111, 745-756. 
In this study we studied the mechanisms by which activation of a persistent sodium current is linked 
to elevation of intracellular Ca2+ levels. The sources of calcium increase, and their temporal aspects 
were investigated. Ca2+ influx through voltage-gated Ca2+ channels and mitochondrial Ca2+ 
sequestration dominated the first, rapid phase, which was followed by a robust second phase, which 
involved reverse operation of the Na+-Ca2+ exchanger and mitochondrial Ca2+ release. 
 
Lenkey, N., Karoly, R., Lukacs, P., Vizi, E. S., Sunesen, M., Fodor, L., Mike, A. 
Classification of drugs based on properties of sodium channel inhibition: a 
comparative automated patch-clamp study.  
PLoS One, 2010, 5, e15568. 
In an attempt to identify sodium channel inhibitors with different state-selectivity, we performed a 
comparative study of 33 SCI drugs using an automated patch clamp instrument. We have shown 
that SCIs are diverse in their modes of action; and identified at least four distinct groups with 
different chemical properties and modes of action. This study was the first step to identify chemical 
properties which determine effectiveness in specific therapeutic actions. We found that aromaticity 
and logD are especially important determinants of inactivated state affinity, and showed that – 
contrary to textbook knowledge – positive charge is not a requirement (it was only found important 
for resting state affinity). 
 
Lenkey, N., Karoly, R., Epresi, N., Vizi, E., Mike, A. 
Binding of sodium channel inhibitors to hyperpolarized and depolarized 
conformations of the channel.  
Neuropharmacology 60, 191-200. 
One of the major hindrances in the development of novel sodium-channel inhibiting drugs is the 
lack of detailed comparative analyses of drug actions. Individual laboratories often provide detailed 
analyses for individual drugs; however, these are not compared with studies in other laboratories on 
other compounds. Large-scale screens for SCIs, on the other hand, provide insufficient useful 
information regarding the modes of drug actions.  
For these reasons, we wanted to devise a way to compare data from individual laboratories. Toward 
this end, we developed a method to calculate resting- and inactivated-state affinities from different 
sets of experimental protocols. Using this method, we compared the affinities of individual drugs. 
Interestingly, we found that SCIs that were therapeutically successful were among the least potent 
drugs, indicating that potency alone is not a good predictor of therapeutic value. It has been 
suggested that the extent of state-dependence (i.e., inactivated state affinity / resting state affinity) is 
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more important in judging the therapeutic potential of a novel compound. Therefore, we performed 
a meta-analysis to ascertain the most important chemical properties that determine a compound’s 
affinity for resting and inactivated states. We showed that aromaticity and logD values are critical in 
determining inactivated-state affinity. (Lenkey, Karoly et al. 2011). 
 
Karoly, R., Lenkey, N., Juhasz, A. O., Vizi, E. S., Mike, A. 
Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and 
experimental study. 
PLoS Comput Biol 6, 2010, e1000818. 
One of the major mechanisms of inhibition by SCIs is related to their high affinities for the 
inactivated state, resulting in the stabilisation of particular inactivated states via drug-bound 
channels. A unique action is expected for each SCI, depending on which of the inactivated states it 
prefers. In recent years, several compounds have been shown to prefer the slow inactivated state. 
However, as we have discussed in an experimental and theoretical paper, there is interaction 
between binding and gating kinetics, making it easy to mistake slow binding kinetics for slow 
inactivated-state preference in studies of SCIs. We have detailed the special situations in which 
specific-state preferences can be determined with confidence.  
 
Mike, A., Lukacs, P. 
The enigmatic drug binding site for sodium channel inhibitors.  
Curr Mol Pharmacol 2010, 3, 129-144. 
We deduced that if SCIs are functionally heterogeneous, they must be heterogeneous in their 
interactions with specific residues within the SCI binding region. We collected all available 
mutagenesis data, and compared data for individual drugs plotted on a homology model of sodium 
channels. We found that while the role of Phe1764 (Nav1.2 numbering) is unquestionably crucial 
for the majority of drugs, its mutation did not cause a significant change of the affinity of eight out 
of 28 drugs. This suggests that an alternative binding site must exist. The other residue, Tyr1771 
which is regarded as the other crucial element of the binding site, did not prove to be special at all; 
mutation of at least five other residues caused similar changes in affinity. Furthermore, based on 
mutagenesis data we proposed that a highly conservative ring of asparagine residues located at the 
outer surface of the pore domain is involved in voltage sensor-gate coupling.  
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Role of different neurotransmitters released into the extracellular space. 
Vizi, E. S., Fekete, A., Karoly, R., Mike, A 
Non-synaptic receptors and transporters involved in brain functions and targets of 
drug treatment.  
Br J Pharmacol, 2010, 160, 785-809. 
Finally, we wrote a general review on nonsynaptic neurotransmission for British Journal of 
Pharmacology, which included discussion of the role of nicotinic, NMDA, adenosine as well as all 
other major receptor types. In addition we considered specific aspects of non-synaptic transmission, 
such as synaptic–extrasynaptic receptor trafficking, neuron–glia communication and retrograde 
signaling. We reviewed structural and functional aspects of non-synaptic transmission, including (i) 
anatomical arrangement of non-synaptic release sites, receptors and transporters, (ii) intravesicular, 
intra- and extracellular concentrations of neurotransmitters, as well as the spatiotemporal pattern of 
transmitter diffusion. We emphasized the role of non-synaptic receptors and transporters as primary 
targets available for pharmacological intervention.  
 
 
Summary:  
There is a long list of neuroprotective compounds that have failed to be clinically useful in the 
treatment of ischaemic stroke (Editorial 2006). This is likely due, at least in part, to our inadequate 
knowledge regarding the core mechanisms of ischaemic diseases. 
Neurodegeneration after a stroke is one of the major causes of present-day morbidity and mortality. 
Cell death produced by excitotoxicity resulting from acute ischaemic brain injuries and chronic 
neurodegeneration is associated with excessive and/or prolonged activation of Glu receptors, 
resulting in the persistent depolarisation of neurons, mitochondrial dysfunction leading to energy 
failure, increased mitochondrial Ca2+ uptake, increased production of reactive oxygen species 
(ROS), increased concentrations of cytosolic Ca2+ and the activation of self-destructing enzymatic 
and nuclear mechanisms. Depolarisation is initiated by the activation of AMPA receptors and 
voltage-dependent Na+ channels, leading to Na+ entry followed by Ca2+ influx and further 
depolarisation. If the cell becomes depolarised, NMDA receptors escape from the Mg2+ block and 
can be activated by synaptic Glu, resulting in further Ca2+ entry into the cell. In addition, the 
intracellular Ca2+ concentrations can be increased through the activation of voltage-dependent Ca2+ 
channels, the opening of NMDA receptor channels and the impairment of membrane Na+/Ca2+ 
exchangers. 
 
- Most “novel” drugs that target the CNS are designed to act on neurotransmitter receptors or 
transporters that are localised within synapses. To develop the most effective drugs, it is 
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important to remember that there extrasynaptic receptors and transporters that may 
outnumber those located within synapses and that, when malfunctioning, may be responsible 
for several symptoms of CNS disorders. There is strong morphological and functional 
evidence that nonsynaptic receptors and transporters are present in the brain and are of 
axonal or somatodendritic localisations. They can be present in silent forms, and they have 
high affinities, enabling them respond to chemical messages arriving from distant axon 
terminals and at low ambient concentrations. (Vizi, Fekete et al. 2010).   
- Extrasynaptic receptors and transporters are easily accessible by drugs and therefore present 
ideal targets for drug therapy at low, non-toxic levels, and their abnormal (excessive, tonic 
or lack of) activation by transmitters that are released into the extracellular space may be 
involved in the pathology of CNS diseases. Synaptic NMDA receptors show anti-apoptotic 
activity, whereas stimulation of extrasynaptic NMDA receptors causes a breakdown of the 
mitochondrial membrane potential. The latter is an early marker for Glu-induced neuronal 
damage, ROS generation (Adam-Vizi 2005) and cell death.   
- Hypoxic/ischaemic conditions induced by the stimulation of extrasynaptic Glu receptors 
have also been found to activate Ca2+-activated chloride channels (ClCa1) (Wahl, Buchthal 
et al. 2009), which are part of the genomic death programme and are also involved in 
causing neuronal damage. It is clear from these data that non-selective NMDA antagonists 
that exert effects on both NR2B and NR2A receptors cannot be efficient neuroprotective 
drugs because they inhibit both the neurotoxic and neuroprotective pathways of NMDA 
transmission. The specific blockade of nonsynaptic NMDA receptors and the search for 
selective NR2B antagonists have, therefore, become primary avenues for drug development. 
 
We suggest that future drug development research consider the following:  
- Compounds that are able to selectively inhibit non-synaptic NR2B Glu receptors and that are 
able to block Na+-channels (such as Fluoxetin); 
- Compounds that are able to prevent the transporter-mediated release of DA (noradrenaline) 
in response to ischaemia (oxidative stress, H2O2), thereby inhibiting the production of toxic 
DA metabolites (i.e., DOPEGAL and DOPAL) and H2O2 production (oxidative stress). 
(Note that released DA produces H2O2 and H2O2 releases DA, thereby forming a destructive 
feedback loop) are candidates for successful treatment of neurodegenerative diseases. 
- compounds able to enhance the effects of nicotinic agonists. They would be potential drugs 
in the treatment of memory problems and in smoking cessation.  
-  
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